Total trials
104
Active
18
Phase 3
1
Total enrollment
8,157
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| GLP-1 receptor agonist | — | — | — | — | — | 1 | |
| SGLT2 inhibitor | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Other drugs | — | — | — | — | — | 1 |
Next readouts
- 2027-07-31
Top conditions
- Obesity7
- Low Back Pain6
- End Stage Renal Disease6
- Hypertension5
- Sarcopenia3
- End Stage Renal Disease on Dialysis3
- Fibromyalgia3
- Pain2
Frequently asked questions about Cardenal Herrera University
- How many clinical trials does Cardenal Herrera University have on ClinicalTrials.gov?
- Cardenal Herrera University is listed as the lead sponsor on 104 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Cardenal Herrera University's trials are in Phase 3?
- 1 of Cardenal Herrera University's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Cardenal Herrera University focus on?
- Cardenal Herrera University's most-studied conditions on ClinicalTrials.gov are Obesity, Low Back Pain, End Stage Renal Disease, Hypertension, Sarcopenia.
- When are Cardenal Herrera University's next clinical trial readouts?
- Cardenal Herrera University has 1 upcoming primary-completion readout tracked here; the soonest is “Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD”, expected around 2027-07-31.